EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

FOXA1 in prostate cancer

Hui-Yu Dong, Lei Ding, Tian-Ren Zhou, Tao Yan, Jie Li, Chao Liang

Asian Journal of Andrology · 2023-05 · 25 (3) · 287-295

DOI: 10.4103/aja202259 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Asian Journal of Andrology, online erschienen am 19.08.2022. Verfasst von Hui-Yu Dong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. Hauptthemen laut MEDLINE: Hepatocyte Nuclear Factor 3-alpha, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Most prostate cancers initially respond to androgen deprivation therapy (ADT). With the long-term application of ADT, localized prostate cancer will progress to castration-resistant prostate cancer (CRPC), metastatic CRPC (mCRPC), and neuroendocrine prostate cancer (NEPC), and the transcriptional network shifted. Forkhead box protein A1 (FOXA1) may play a key role in this process through multiple mechanisms. To better understand the role of FOXA1 in prostate cancer, we review the interplay among FOXA1-targeted genes, modulators of FOXA1, and FOXA1 with a particular emphasis on androgen receptor (AR) function. Furthermore, we discuss the distinct role of FOXA1 mutations in prostate cancer and clinical significance of FOXA1 . We summarize possible regulation pathways of FOXA1 in different stages of prostate cancer. We focus on links between FOXA1 and AR, which may play different roles in various types of prostate cancer. Finally, we discuss FOXA1 mutation and its clinical significance in prostate cancer. FOXA1 regulates the development of prostate cancer through various pathways, and it could be a biomarker for mCRPC and NEPC. Future efforts need to focus on mechanisms underlying mutation of FOXA1 in advanced prostate cancer. We believe that FOXA1 would be a prognostic marker and therapeutic target in prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatocyte Nuclear Factor 3-alphaProstatic Neoplasms, Castration-ResistantHumansMaleAndrogen AntagonistsAndrogensMutationReceptors, Androgen

Stichwörter der Autor:innen

androgen receptorforkhead box protein A1mutationprostate cancer

Substanzen

Androgen AntagonistsAndrogensFOXA1 protein, humanHepatocyte Nuclear Factor 3-alphaReceptors, Androgen

Autor:innen und Institutionen

  • Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
  • Department of Clinical Medicine, Suzhou Vocational Health College, Suzhou 215009, China.

Zitieren

APA

Dong, H. Y., Ding, L., Zhou, T. R., Yan, T., Li, J., & Liang, C. (2023). FOXA1 in prostate cancer. Asian Journal of Andrology, 25(3), 287-295. https://doi.org/10.4103/aja202259

Vancouver

Dong HY, Ding L, Zhou TR, Yan T, Li J, Liang C. FOXA1 in prostate cancer. Asian Journal of Andrology. 2023;25(3):287-295. doi:10.4103/aja202259

BibTeX
@article{Dong2023,
  author = {Dong, Hui-Yu and Ding, Lei and Zhou, Tian-Ren and Yan, Tao and Li, Jie and Liang, Chao},
  title = {FOXA1 in prostate cancer},
  journal = {Asian Journal of Andrology},
  year = {2023},
  volume = {25},
  number = {3},
  pages = {287--295},
  doi = {10.4103/aja202259}
}
Kostenlos starten →